Chronic Obstructive Pulmonary Disease Segment to Lead Spirometer Market During 2022-2028

According to our latest study on "Spirometer Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Type, Technology, and Application," the market is expected to grow from US$ 893.71 million in 2021 to US$ 1,907.36 million by 2028; it is estimated to grow at a CAGR of 11.5% from 2022 to 2028. The report highlights the key factors and trends impacting the market and focuses on prominent players and their strategies.

Spirometer is a diagnostic device that measures the circulation of air into and out of the lungs. Obstructive and restrictive aberrant ventilation patterns are identified using the spirogram. Spirometer is the primary preferred equipment used for basic pulmonary function tests (PFTs). The tests may rule out lung illnesses, including asthma, bronchitis, and emphysema.

The higher prevalence of respiratory disorders is related to the decrease in the size of the upper airway lumen in the aging population. Millions of people across the world are suffering from various types of respiratory diseases. Moreover, smoking, genetic factors, and infections are among the common factors responsible for respiratory diseases. Medical conditions such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, and lung cancer are significant public health burdens.

According to a report published by the Global Initiative on Chronic Obstructive Lung Disease, ~65 million people suffer from COPD, and ~3 million people die from the disease across the world, making it the third leading cause of mortality. Besides, as recommended by the WHO, 91% of the world's population lives in cities and places where the air quality is not optimum. According to the US Department of Health and Human Services, 25 million people in the US had asthma in 2019, known to be the most common respiratory disease. About 262 million people were affected by asthma worldwide in 2019, which resulted in 455,000 deaths, as per a WHO study. With the increasing prevalence of smoking in developing countries and the aging population in high-income countries, incidence of COPD is projected to rise in the next 40 years. Moreover, by 2060, it is estimated that there will be more than 5.4 million deaths each year due to COPD and related conditions.

Thus, early detection and diagnosis of respiratory diseases can help treat the patients with these diseases. In such cases, spirometry serves as a crucial technology that assists in indulging in the severity of the infection and avoids misdiagnosis. Thus, the increasing incidence of respiratory diseases drives the growth of the spirometer market.

Based on application, the spirometer market is segmented into asthma, chronic obstructive pulmonary disease, cystic fibrosis, and others. The chronic obstructive pulmonary disease segment holds the largest share of the market in 2022. However, the asthma segment is expected to register the highest CAGR during 2022-2028. The term chronic obstructive pulmonary disease (COPD) refers to a group of conditions characterized by progressive development of airflow limitation that is usually not fully reversible with medication treatment. Chronic obstructive bronchitis, a chronic inflammation to lower respiratory track, and emphysema, a complex lung disease characterized by damage to alveoli, are two serious conditions that cause COPD. The primary cause of COPD is tobacco smoking. Additionally, ambient air pollution, occupational exposure, and passive smoking can cause COPD.

According to a Medscape article from April 2019, the prevalence of COPD varies from 7 to 19% across the world. As per WHO, nearly 90% of COPD deaths occur in geriatric population (more than 70 years) in low- and middle-income countries.

As COPD is a major cause of death worldwide, there is a need for continued monitoring of its prevalence in the population. The inclusion of spirometer in the practice for the diagnostic of COPD will drive the spirometer market growth for the chronic obstructive pulmonary disease segment in the coming years.

Impact of COVID-19 Pandemic on Spirometer Market

Respiratory diseases are among the leading causes of deaths across the world, and the incidence of respiratory diseases is increased worldwide due to the COVID-19 outbreak. During the lockdown periods, the healthcare industry encountered unprecedented challenges. Manufacturing units were closed, affecting the production of medical devices and other equipment. Moreover, the supply chains of medical products were disrupted, resulting in an increase in warehouse inventory of manufactured products. Hence, at the initial stage of the pandemic, the spirometer market was adversely affected. As per the recommendations by the New Zealand and the Irish Thoracic Society, the Thoracic Society of Australia, and the American Thoracic Society, pulmonary function tests and planned pulmonary visits were either suspended or postponed during the initial months of the pandemic, except for critical cases. In addition, the Italian Thoracic Society (ITS), in collaboration with the Italian Society of Hospital Pneumologists (AIPO) in the Paper published in May 2020, recommended in the early stages of the pandemic that functional respiratory tests be performed only when necessary, and nonurgent cases that can be managed at home to be postponed. The Italian Pediatric Respiratory Society (IPRS/SIMRI) recommends that respiratory tests, when necessary, should be limited to spirometry and performed only if there are urgent therapeutic decisions in children with chronic pulmonary diseases, such as cystic fibrosis, severe uncontrolled asthma, and other diseases.

The use of spirometers during the COVID-19 pandemic is higher as the infection of the novel coronavirus is highly related to lung complications, including pneumonia-like conditions and in the most severe cases, acute respiratory distress syndrome (ARDS). Manufacturers witnessed increased product demand from healthcare professionals and patients to monitor their lung functions at home. Technologically advanced respiratory health management companies have developed digital spirometers that enable patients to easily monitor their lung function. Thus, post pandemic, increased preference for home healthcare is expected to create new opportunities for the spirometer market.

Jones Medical Instrument Company; Benson Medical Instruments Co.; NUVOAIR US, INC. (NUVOAIR AB); Teleflex Incorporated; Vyaire Medical, Inc.; COSMED srl; Depisteo LLC; Henry Schein, Inc; Baxter International Inc.; and ICU Medical Inc. are among the key players operating in the spirometer market.

The report segments the spirometer market as follows:

The spirometer market is segmented on the basis of type, technology, application, and geography. Based on type, the market is segmented into handheld spirometers, table-top spirometers, and desktop spirometers. By technology, the spirometer market is segmented into volume, flow, and peak flow. Based on application, the market is segmented into asthma, chronic obstructive pulmonary disease, cystic fibrosis, and others. Geographically, the spirometer market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of SAM).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com